RAB11A and pancreatic neoplasm: In a study of resistance to gemcitabine in pancreatic cancer [43], researchers used small interfering RNA (siRNA) to verify that overexpression of Rab11a could increase the resistance of Capan-2 cells to gemcitabine and inhibit apoptosis induced by gemcitabine, while the absence of Rab11a reduced drug resistance.